Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “outperform” rating reiterated by Cowen and Company in a note issued to investors on Wednesday. They presently have a $117.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $93.00. Cowen and Company’s target price suggests a potential upside of 2.83% from the stock’s previous close.

Several other research firms also recently weighed in on ALNY. Jefferies Group LLC set a $102.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Barclays PLC upped their price target on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 10th. Credit Suisse Group upped their price target on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 27th. BMO Capital Markets restated an “outperform” rating and set a $99.00 price target (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Finally, Leerink Swann restated a “market perform” rating and set a $72.00 price target (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $87.59.

Shares of Alnylam Pharmaceuticals (ALNY) traded up 51.71% on Wednesday, hitting $113.84. The stock had a trading volume of 18,362,421 shares. The firm’s 50-day moving average price is $81.14 and its 200 day moving average price is $69.12. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $116.93. The firm’s market cap is $10.44 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same quarter last year, the company earned ($1.05) EPS. The firm’s revenue for the quarter was up 82.9% on a year-over-year basis. Analysts anticipate that Alnylam Pharmaceuticals will post ($5.19) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals’ (ALNY) “Outperform” Rating Reiterated at Cowen and Company” was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US and international copyright and trademark laws. The original version of this piece of content can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-alny-outperform-rating-reiterated-at-cowen-and-company/1576538.html.

Large investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $148,000. QS Investors LLC boosted its position in shares of Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 900 shares during the period. Westpac Banking Corp purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $202,000. The Manufacturers Life Insurance Company boosted its position in shares of Alnylam Pharmaceuticals by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $215,000. 94.25% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.